John Nicholson Sells 4,077 Shares of Nektar Therapeutics (NKTR) Stock

Nektar Therapeutics (NASDAQ:NKTR) COO John Nicholson sold 4,077 shares of the company’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $31.37, for a total value of $127,895.49. Following the completion of the sale, the chief operating officer now directly owns 166,578 shares of the company’s stock, valued at $5,225,551.86. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

John Nicholson also recently made the following trade(s):

  • On Tuesday, February 19th, John Nicholson sold 3,822 shares of Nektar Therapeutics stock. The shares were sold at an average price of $42.39, for a total value of $162,014.58.

Nektar Therapeutics stock traded up $0.68 during mid-day trading on Friday, reaching $32.02. 1,705,490 shares of the company were exchanged, compared to its average volume of 1,645,948. Nektar Therapeutics has a twelve month low of $29.22 and a twelve month high of $92.17. The company has a current ratio of 14.94, a quick ratio of 14.83 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $5.46 billion, a price-to-earnings ratio of 8.47 and a beta of 2.96.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.03. Nektar Therapeutics had a return on equity of 37.63% and a net margin of 55.65%. The company had revenue of $28.22 million during the quarter, compared to analysts’ expectations of $25.45 million. During the same period last year, the firm earned ($0.60) EPS. Equities analysts predict that Nektar Therapeutics will post -3.14 earnings per share for the current year.

Institutional investors have recently bought and sold shares of the business. Meeder Asset Management Inc. lifted its position in Nektar Therapeutics by 150.2% during the 1st quarter. Meeder Asset Management Inc. now owns 798 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 479 shares during the period. Quantamental Technologies LLC acquired a new stake in Nektar Therapeutics during the 1st quarter worth approximately $27,000. CSat Investment Advisory L.P. lifted its position in Nektar Therapeutics by 279.2% during the 4th quarter. CSat Investment Advisory L.P. now owns 1,073 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 790 shares during the period. Laurel Wealth Advisors LLC acquired a new stake in Nektar Therapeutics during the 4th quarter worth approximately $39,000. Finally, Sandy Spring Bank acquired a new stake in Nektar Therapeutics during the 4th quarter worth approximately $59,000. 94.90% of the stock is owned by institutional investors.

NKTR has been the subject of a number of research analyst reports. BidaskClub cut Nektar Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, April 18th. Piper Jaffray Companies set a $100.00 target price on Nektar Therapeutics and gave the company a “buy” rating in a research report on Friday, March 1st. Mizuho reissued a “buy” rating and issued a $81.00 target price on shares of Nektar Therapeutics in a research report on Wednesday, January 23rd. ValuEngine raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 1st. Finally, Leerink Swann initiated coverage on Nektar Therapeutics in a research report on Friday, March 15th. They issued a “market perform” rating for the company. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $69.73.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/05/18/john-nicholson-sells-4077-shares-of-nektar-therapeutics-nktr-stock.html.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

Recommended Story: Conference Calls

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.